Business
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
PONTE VEDRA, Fla., June 12, 2025--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/242a270be78377c365bb1d8b66329ea9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wkHBU9xS5NVOkeuAajqb5w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/242a270be78377c365bb1d8b66329ea9","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/J8Gz2Y0Q10IeYyf7kO.KDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/242a270be78377c365bb1d8b66329ea9","width":1200,"height":278}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":415,"olType":false},{"type":"text","content":"PONTE VEDRA, Fla., June 12, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.","length":405,"tagName":"p"},{"type":"text","content":"The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:","length":318,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Major bleeds remai...